PYY3-36 infused systemically or directly into the VTA attenuates fentanyl seeking in male rats

A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss

(2023) Kylie S. Chichura et al.   Scientific Reports

Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review

(2022) Céline Nicolas et al.   PHARMACOLOGICAL REVIEWS

Sex- and Dose-Dependent Differences in the Development of an Addiction-Like Phenotype Following Extended-Access Fentanyl Self-Administration

(2022) Eleanor Blair Towers et al.   Frontiers in Pharmacology

Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats

(2022) Luke A. Urbanik et al.   BRAIN RESEARCH BULLETIN

Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis

(2021) Brandon T. Milliken et al.   JOURNAL OF MEDICINAL CHEMISTRY

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neuropeptide Y Y2 and Y5 receptors as potential targets for neuroprotective and antidepressant therapies: Evidence from preclinical studies

(2021) Helena Domin   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Escalation and reinstatement of fentanyl self-administration in male and female rats

(2021) Samantha G. Malone et al.   PSYCHOPHARMACOLOGY

A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats

(2021) Yafang Zhang et al.   NEUROPHARMACOLOGY

Glucagon‐like peptide‐1 receptor agonist, liraglutide, reduces heroin self‐administration and drug‐induced reinstatement of heroin‐seeking behaviour in rats

(2021) Joaquin E. Douton et al.   ADDICTION BIOLOGY

A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors

(2021) Riley Merkel et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Sex differences in behavioral and metabolic effects of gene inactivation: The neuropeptide Y and Y receptors in the brain

(2020) Carola Eva et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA

(2020) Nicole S. Hernandez et al.   MOLECULAR PSYCHIATRY

A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates

(2019) Shamina M. Rangwala et al.   Cell Metabolism

NPY 2 receptor activation in the dorsal vagal complex increases food intake and attenuates CCK-induced satiation in male rats.

(2019) Nathaneal Jason Huston et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats

(2019) Yafang Zhang et al.   NEUROPSYCHOPHARMACOLOGY

GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence

(2018) Elisabet Jerlhag   NEUROPHARMACOLOGY

Relapse to opioid seeking in rat models: behavior, pharmacology and circuits

(2018) David J. Reiner et al.   NEUROPSYCHOPHARMACOLOGY

Prevention and Treatment of Opioid Misuse and Addiction

(2018) Nora D. Volkow et al.   JAMA Psychiatry

PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice

(2018) Marina Kjaergaard et al.   NEUROPEPTIDES

GLP-1 acts on habenular avoidance circuits to control nicotine intake

(2017) Luis M Tuesta et al.   NATURE NEUROSCIENCE

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

(2017) Mirko Sikirica et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

(2016) Karolin Bettge et al.   DIABETES OBESITY & METABOLISM

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice

(2015) Gunnar Sørensen et al.   PHYSIOLOGY & BEHAVIOR

Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men

(2014) Julie Berg Schmidt et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Compulsive-Like Responding for Opioid Analgesics in Rats with Extended Access

(2014) Carrie L Wade et al.   NEUROPSYCHOPHARMACOLOGY

The Y2 receptor agonist PYY3–36 increases the behavioural response to novelty and acute dopaminergic drug challenge in mice

(2013) Ulrike Stadlbauer et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Opiate-Induced Molecular and Cellular Plasticity of Ventral Tegmental Area and Locus Coeruleus Catecholamine Neurons

(2013) M. S. Mazei-Robison et al.   Cold Spring Harbor Perspectives in Medicine

Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance

(2013) Keval Chandarana et al.   Molecular Metabolism

Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats

(2012) Blake A. Kimmey et al.   ADDICTION BIOLOGY

Possible Mechanisms of Circulating PYY-Induced Satiation in Male Rats

(2012) Ulrike Stadlbauer et al.   ENDOCRINOLOGY

The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans

(2011) Akila De Silva et al.   Cell Metabolism

Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass

(2011) W K Fenske et al.   INTERNATIONAL JOURNAL OF OBESITY

Characterization of NPY Y2 receptor protein expression in the mouse brain. II. Coexistence with NPY, the Y1 receptor, and other neurotransmitter-related molecules

(2011) Davor Stanić et al.   JOURNAL OF COMPARATIVE NEUROLOGY

The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide

(2011) Scott E. Kanoski et al.   NEUROPHARMACOLOGY

Comparative Effects of the Long-Acting GLP-1 Receptor Ligands, Liraglutide and Exendin-4, on Food Intake and Body Weight Suppression in Rats

(2011) Matthew R. Hayes et al.   Obesity

Peptide YY

(2011) Keval Chandarana et al.   Current Opinion in Endocrinology Diabetes and Obesity

Peptide hormones regulating appetite-focus on neuroimaging studies in humans

(2010) Haiko Schloegl et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Effects of Exendin-4 Alone and With Peptide YY3–36 on Food Intake and Body Weight in Diet-Induced Obese Rats

(2010) Roger D. Reidelberger et al.   Obesity

Gene expression changes following extinction testing in a heroin behavioral incubation model

(2009) Kara L Kuntz-Melcavage et al.   BMC NEUROSCIENCE

Food deprivation-like effects of neuropeptide Y on heroin self-administration and reinstatement of heroin seeking in rats

(2008) Tia Maric et al.   BEHAVIOURAL BRAIN RESEARCH

Neurobiological substrates for the dark side of compulsivity in addiction

(2008) George F. Koob   NEUROPHARMACOLOGY

PYY(3–36) induces Fos in the arcuate nucleus and in both catecholaminergic and non-catecholaminergic neurons in the nucleus tractus solitarius of rats

(2007) J.E. Blevins et al.   PEPTIDES